889PClinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. (23rd October 2018) - Graham, J; Wells, J C; McKay, R; Vaishampayan, U N; Hansen, A; Donskov, F; Bjarnason, G A; Beuselinck, B; De Velasco, G; Duh, M S; Huynh, L; Chang, R; et al.